Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,934,719
  • Shares Outstanding, K 49,010
  • Annual Sales, $ 80 K
  • Annual Income, $ -349,140 K
  • 36-Month Beta 1.05
  • Price/Sales 65.18
  • Price/Cash Flow N/A
  • Price/Book 8.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.78 +21.50%
on 02/09/18
64.43 -11.78%
on 01/24/18
-7.26 (-11.33%)
since 01/23/18
3-Month
46.78 +21.50%
on 02/09/18
69.02 -17.65%
on 12/29/17
-4.68 (-7.61%)
since 11/22/17
52-Week
45.42 +25.14%
on 05/11/17
99.45 -42.85%
on 07/28/17
-0.87 (-1.51%)
since 02/23/17

Most Recent Stories

More News
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Industry Analysis & Outlook (2018-2025) - Multiple Growth Factors are Driving the Market - ResearchAndMarkets.com

The "Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Industry Analysis & Outlook (2018-2025)" report has been added to ResearchAndMarkets.com's offering.

CLVS : 56.84 (-5.08%)
TSRO : 60.74 (-0.25%)
Today's Research Reports on Trending Tickers: Sangamo Therapeutics and Clovis Oncology

NEW YORK, NY / ACCESSWIRE / February 23, 2018 / U.S. equities recovered on Thursday with the Dow Jones and S&P 500 closing in the green. The Federal Reserve released minutes from their Wednesday meeting...

SGMO : 24.95 (-1.77%)
CLVS : 56.84 (-5.08%)
Is a Surprise Coming for Clovis Oncology (CLVS) This Earnings Season?

Clovis Oncology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

CLVS : 56.84 (-5.08%)
Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.S. financial markets. Clovis'...

CLVS : 56.84 (-5.08%)
Watch for Clovis Oncology to Potentially Rebound After Falling 1.74% Yesterday

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $55.65 to a high of $58.30. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $56.38...

CLVS : 56.84 (-5.08%)
Look for Shares of Clovis Oncology to Potentially Rebound after Yesterday's 2.07% Sell Off

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $58.51 to a high of $60.70. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $59.88...

CLVS : 56.84 (-5.08%)
Watch for Clovis Oncology to Potentially Pullback After Gaining 4.78% Yesterday

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $57.34 to a high of $59.89. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of...

CLVS : 56.84 (-5.08%)
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.

AZN : 34.01 (+0.95%)
MRK : 54.87 (+0.55%)
CLVS : 56.84 (-5.08%)
TSRO : 60.74 (-0.25%)
After Yesterday's Decline of 5.64%, Clovis Oncology Offers Investors Better Value

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $55.10 to a high of $60.04. Yesterday, the shares fell 5.6%, which took the trading range below the 3-day low of $57.70...

CLVS : 56.84 (-5.08%)
AstraZeneca's Lynparza Label Now Includes Breast Cancer

AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

AZN : 34.01 (+0.95%)
MRK : 54.87 (+0.55%)
MYGN : 33.14 (+1.35%)
CLVS : 56.84 (-5.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 61.71
1st Resistance Point 59.28
Last Price 56.84
1st Support Level 55.37
2nd Support Level 53.90

See More

52-Week High 99.45
Fibonacci 61.8% 78.81
Fibonacci 50% 72.43
Fibonacci 38.2% 66.06
Last Price 56.84
52-Week Low 45.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.